EPOCH方案和CHOP方案一线治疗非特指型外周T细胞淋巴瘤的疗效比较  

Comparison of the efficacy of EPOCH regimen and CHOP regimen in the treatment of non-specific peripheral T-cell lymphoma

作　　者：杨玉红 楼大勇 YANG Yu-hong;LOU Da-yong(Department of Hematology,Zhuji People’s Hospital,Zhuji,Zhejiang 311800,China;不详)

机构地区：[1]诸暨市人民医院血液科,浙江诸暨311800 [2]诸暨市人民医院药剂科,浙江诸暨311800

出　　处：《中华全科医学》2020年第9期1490-1492,1499,共4页Chinese Journal of General Practice

基　　金：浙江省医药卫生科技计划项目(2019PY016)。

摘　　要：目的回顾性分析非特指型外周T细胞淋巴瘤(PTCL-NOS)患者经EPOCH化疗方案或标准CHOP化疗方案一线治疗的临床获益。方法收集2014年1月—2016年12月诸暨市人民医院收诊的84例初治PTCL-NOS患者的临床资料做回顾性分析。依据化疗方案分为EPOCH组(39例,经EPOCH方案化疗)和CHOP组(45例,经标准CHOP方案化疗)。考察并比较PTCL-NOS患者经2种化疗方案治疗的近期临床疗效(客观缓解率ORR)、远期临床疗效(1年、2年、3年生存率OS)及安全性。结果 EPOCH组的CR率为53.85%,ORR率为76.92%;CHOP组的CR率为26.67%,ORR率为66.67%,2组CR率差异有统计学意义(χ^2=6.470,P=0.011),ORR率差异无统计学意义(χ^2=0.030,P=0.872)。2组中性粒细胞减少、胃肠道反应、血小板减少、贫血及肝功能损伤等ADR发生率比较差异均无统计学意义(均P>0.05)。2组1年OS率比较,差异无统计学意义(P>0.05)。EPOCH组的1年OS率74.36%,2年OS率69.23%、3年OS率64.10%,CHOP组分别为68.89%、53.33%、46.67%;2组1年OS率(χ^2=0.010,P=0.932),2年OS率(χ^2=0.050,P=0.818)、3年OS率(χ^2=0.060,P=0.804)比较,差异均无统计学意义。结论一线治疗PTCL-NOS患者采用EPOCH化疗方案可以获得与标准CHOP化疗方案相一致的临床疗效,患者多能耐受不良反应,而EPOCH方案中均为临床常用药物,故推荐其为治疗PTCL-NOS患者的首选一线方案。Objective To retrospectively analyze the clinical benefits of the first-line treatment of non-specific peripheral T cell lymphoma(PTCL-NOS)patients with EPOCH chemotherapy or standard CHOP chemotherapy.Methods The clinical data of 84 newly treated patients with PTCL-NOS from January 2014 to December 2016 were collected and analyzed retrospectively.According to different chemotherapy regimen,they were divided into EPOCH group(39 cases,treated with EPOCH regimen)and CHOP group(45 cases,treated with standard CHOP regimen).The short-term clinical efficacy(objective response rate ORR),long-term clinical efficacy(1-year,2-year,3-year survival rate OS)and safety of PTCL-NOS patients treated with two chemotherapy regimens were investigated and compared.Results The CR rate of EPOCH group was 53.85%,ORR rate was 76.92%,while the CR rate of CHOP group was 26.67%,ORR rate was 66.67%.There was significant difference in CR rate between the two groups(χ^2=6.470,P=0.011),and no significant difference in ORR rate(χ^2=0.030,P=0.872).There was no significant difference in ADR incidence rate between the two groups(all P>0.05),including neutropenia,gastrointestinal reaction,thrombocytopenia,anemia and liver function damage.There was no significant difference between the two groups in 1-year OS rate(P>0.05).The 1-year,2-year and 3-year OS rate of EPOCH group were 74.36%,69.23%and 64.10%,and those of CHOP group were 68.89%,53.33%and 46.67%,there was no significant difference between the two groups in 1-year(χ^2=0.010,P=0.932)2-year OS rate(χ^2=0.050,P=0.818)and 3-year OS rate(χ^2=0.060,P=0.804).Conclusion The first-line treatment of PTCL-NOS patients with EPOCH chemotherapy regimen can obtain the same clinical effect as the standard CHOP chemotherapy regimen,patients can tolerate adverse reactions,and EPOCH regimen combination drugs are commonly used clinical drugs,so it is recommended as the first-line treatment of PTCL-NOS patients.

关 键 词：EPOCH方案 CHOP方案 一线化疗方案 非特指型外周T细胞淋巴瘤 临床获益 

分 类 号：R733[医药卫生—肿瘤] R730.53[医药卫生—临床医学]